Anti-Human CD70 Recombinant Antibody (Vorsetuzumab) (CAT#: TAB-H76)

Figure 1 Treatment with vorsetuzumab and KWAR23 led to strong inhibition of tumor growth in SRG mice.

Tumor growth in SRG mice treated with PBS (n = 7), vorsetuzumab (n = 3), vorsetuzumab + KWAR23 (n = 5), or bispecific anti-CD70/KWAR23 (n = 6). The color of the stars indicates comparison of the PBS group with the corresponding treatment group. ns, not significant.

Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J. P., George, B. M., ... & Zheng, Y. (2017). Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences, 114(49), E10578-E10585.

Figure 2 In vitro experiments show that KWAR23 only moderately induced macrophage phagocytosis of four different renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1) following incubation with the anti-human CD70 antibody vorsetuzumab.

Phagocytosis of four different renal carcinoma cells by human macrophages following treatment with vorsetuzumab, vorsetuzumab + KWAR23, bispecific anti-human CD70/KWAR23, and anti-human CD47 antibody (n = 4). Mean ± SEM is shown. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (unpaired two-tailed Student's t test).

Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J. P., George, B. M., ... & Zheng, Y. (2017). Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences, 114(49), E10578-E10585.

Figure 1 Anti-Human CD70 Recombinant Antibody (TAB-H76) in ELISA

ELISA analysis of TAB-H76 was performed by coating with Recombinant Human CD70, His tag. Then blocked with BSA, and incubated TAB-H76. The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.